Skip to content
Biodatica
Start free

Medanta, The Medicity, India

Gurgaon, Haryana

OncologyGrant-only
Compare Sign in to watch

What changed

Study registered, no phase assigned: Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation

4mo agoTrial registeredMar 3, 2026Source filing (opens the source filing in a new tab)

Momentum

75no change

Momentum 75 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

15,632 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jan 20, 2024

    Type2diabetes · COMPLETED · sponsor: Medanta, The Medicity, India · Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes

    ClinicalTrials.gov · NCT06289387 (opens the source filing in a new tab)

  2. Trial

    NA registered

    Jan 1, 2024

    Type 2 Diabetes · COMPLETED · sponsor: Medanta, The Medicity, India · Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

    ClinicalTrials.gov · NCT06187285 (opens the source filing in a new tab)

  3. Trial

    NA registered

    Oct 30, 2023

    Liver Transplant; Complications, Diabete Mellitus · RECRUITING · sponsor: Medanta, The Medicity, India · Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

    ClinicalTrials.gov · NCT06060392 (opens the source filing in a new tab)

  4. Trial

    NA registered

    Jan 1, 2022

    Diabetes Mellitus, Liver Transplant; Complications · COMPLETED · sponsor: Medanta, The Medicity, India · Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation

    ClinicalTrials.gov · NCT05042505 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources